Skip to content
Screener

Nuvation Bio NUVB Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$4.8MBeat by $1.2M
EPS-$0.17In line
Revenue estimate$3.6M
EPS estimate-$0.17

Next report

Nov 2, 2026 (in a month)
Revenue estimate$35.3M
EPS estimate-$0.12

Financials

Q2 2025

Income statement

See full
Revenue$4.8M+237%
Gross profit$2.3M+2,465%
Operating income-$63.6M+86.5%
Net income-$59.0M+87.2%
EPS (diluted)-$0.17+91.0%

Balance sheet

See full
Cash & equivalents$248.0M+623%
Total debt$57.8M+293%
Total equity$372.9M+45.0%
Total assets$647.2M+8.8%

Cash flow

See full
Operating cash flow-$48.2M-29.1%
CapEx$181.0K—
Free cash flow-$48.4M-29.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$697.54M+9.1%
Enterprise value$507.33M-18.2%
P/S48.6×-397×

Profitability

See full
Gross margin27.5%+21.4pp
Operating margin-1,564.9%-766pp
Net margin-1,413.4%-692pp
FCF margin-1,173.2%-522pp

Returns & leverage

See full
Return on equity-64.4%-19.8pp
Debt / equity0.2×+0.1×
Current ratio9.4×-2.1×

Segments

By product

See full
License$3.6M+151%
Research And Development Service Revenue$2.2M+53.3%
Product Revenue$800.0K—
Royalty Revenue$200.0K—

FAQ

When did Nuvation Bio report Q2 2025 earnings?
Nuvation Bio (NUVB) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Nuvation Bio's Q2 2025 revenue and EPS?
Nuvation Bio reported revenue of $4.8M and eps of $-0.17 for Q2 2025.
Did Nuvation Bio beat estimates in Q2 2025?
Revenue beat the consensus estimate of $3.6M by $1.2M. EPS beat the consensus estimate of $-0.17 by $0.00.
How did Nuvation Bio's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 236.8% from $1.4M a year earlier and eps declined 13.3% from $-0.15.
Where can I find Nuvation Bio's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-174954) and the 10-Q periodic report (0000950170-25-104626) directly on SEC EDGAR. The filing index links above go to sec.gov.